The female polyurethane condom (FPC) is a relatively new medical device designed for contraception and the prevention of sexually transmitted infections. Over the past fifteen years, in vitro studies on efficacy, tolerability, and acceptability, as well as clinical trials, have demonstrated that it is virtually safe and at least as effective as the male condom (MCP). In France, it was introduced to the market in 1998–1999, but it remains little used and poorly understood by healthcare professionals. The objective of this study is to provide recommendations regarding information, insertion, and use of the FCP.